for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Agenus Inc

AGEN.OQ

Latest Trade

2.60USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.55

 - 

3.86

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.60
Open
--
Volume
--
3M AVG Volume
17.66
Today's High
--
Today's Low
--
52 Week High
3.86
52 Week Low
1.55
Shares Out (MIL)
137.31
Market Cap (MIL)
362.51
Forward P/E
-2.55
Dividend (Yield %)
--

Next Event

Agenus Inc Annual Shareholders Meeting

Latest Developments

More

Agenus Q2 Loss Per Share $0.38

Agenus Reports Q1 Results

Agenus Reports Q4 Loss Per Share Of $0.40

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Agenus Inc

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Industry

Biotechnology & Drugs

Contact Info

3 Forbes Rd

+1.781.6744400

http://agenusbio.com/

Executive Leadership

Garo H Armen

Chairman of the Board, Chief Executive Officer, Founder, Director

Jennifer S. Buell

Chief Operating Officer

Alexander Duncan

Chief Technology Officer and Head - Research

Christine M. Klaskin

Chief Accounting Officer, Vice President - Finance

Evan Kearns

Vice President, General Counsel, Secretary

Key Stats

1.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-1.460

2017

-1.230

2018

-1.440

2019(E)

-1.035
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.16
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-137.38
Return on Equity (TTM)
-69.11

Latest News

Latest News

Agenus shares soar after cancer therapy deal with Gilead

Shares of Agenus Inc surged as much as 70 percent on Thursday after the company said it would develop and market up to five of its immuno-oncology therapies in partnership with Gilead Sciences Inc.

Gilead, Agenus sign deal to develop immuno-oncology therapies

Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies.

BRIEF-Agenus Inc Says Terminated Controlled Equity Offering Sales Agreement With Cantor Fitzgerald & Co

* AGENUS INC - ON MAY 7 TERMINATED CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD & CO

BRIEF-Agenus Q1 Loss Per Share $0.53

* AGENUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Agenus Reports Q4 Loss Per Share $0.35

* AGENUS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Agenus Inc Files For Sale Of Up 10 Mln Shares Of Common Stock By Selling Stockholders

* AGENUS INC FILES FOR SALE OF UP 10 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text (http://bit.ly/2n84why) Further company coverage:

BRIEF-Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1

* AGENUS ANNOUNCES COMBINATION CLINICAL TRIALS OF ITS ANTI-CTLA4 (AGEN1884) & ANTI-PD1 (AGEN2034)

BRIEF-Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners

* AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS

BRIEF-Agenus reports Q3 loss per share $0.37

* Agenus reports third quarter 2017 financial results and provides corporate update

BRIEF-Agenus files for mixed shelf of up to $250 million

* Agenus Inc files for mixed shelf of up to $250 million – SEC filing Source text - (http://bit.ly/2yzul1n) Further company coverage:

UPDATE 2-'Impressed' FDA panel unanimously recommends GSK shingles vaccine

A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

BRIEF-Agenus Inc Q2 loss per share $0.32

* Agenus reports second quarter 2017 financial results and provides corporate update

BRIEF-AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

* AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

BRIEF-Agenus Q1 loss per share $0.18

* Agenus reports first quarter 2017 financial results and provides corporate update

BRIEF-Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

* Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

BRIEF-Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

* Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

BRIEF-Agenus says plans to close Basel site, combine key functions to Cambridge, UK and Lexington, MA facilities

* Agenus restructures business to sharpen focus on clinical development of cancer therapies

BRIEF-Incyte and Agenus amend collaboration agreement

* Incyte Corp - amended agreement converts ongoing GITR and ox40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs

BRIEF-Venbio Select Advisor LLC reports a 5.41 pct passive stake in Agenus

* Venbio Select Advisor Llc reports a 5.41 passive stake in Agenus Inc as on December 31, 2016 - sec filing Source text - http://bit.ly/2lpg9SS Further company coverage:

BRIEF-QVT Financial reports 5.08 pct passive stake in Agenus

* QVT Financial Lp reports a 5.08 percent passive stake in Agenus Inc as of January 24, 2017 - sec filing Source text - http://bit.ly/2jHW6OQ Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up